晚期肺腺癌接受一线表皮生长因子受体-酪氨酸激酶抑制剂治疗患者的不良预后CT表现
纳入199例IIIB或IV期肺腺癌患者,分析一线EGFR-TKI治疗前CT表现与无进展生存期和总生存期的相关性。多因素分析显示胸腔积液和N2或N3分期与较短无进展生存期显著相关;年龄较大、N2或N3分期、胸腔积液和远处转移与较短总生存期相关。结论认为治疗前CT示胸腔积液和高N分期提示预后不良。
要点
- 治疗前CT示胸腔积液者无进展生存期和总生存期均较短。
- 治疗前CT示N2或N3分期者无进展生存期和总生存期均较短。
- 远处转移与较短总生存期相关,年龄较大亦与较短总生存期相关。
核心结论
- 一线EGFR-TKI治疗前CT示胸腔积液和高N分期肿瘤与肺腺癌患者较短的无进展生存期和总生存期相关。
研究设计与样本
- 回顾性分析199例(男71例、女128例;平均年龄64.3±11.2岁)IIIB或IV期肺腺癌患者,均接受一线EGFR-TKI治疗,治疗时间为2009年1月至2015年12月。
关键影像表现/征象
- 分析治疗前CT的肿瘤大小、TNM分期(美国癌症联合委员会肺癌TNM分期系统第7版)、肿瘤类型、空洞或坏死、胸腔积液及胸膜、肺和远处器官转移。
- 疗效评价依据实体瘤疗效评价标准1.1版。
- 采用Cox比例风险模型评估临床和影像表现与无进展生存期和总生存期的相关性。
诊断标准与关键数值
- 多因素分析中,胸腔积液与较短无进展生存期显著相关(HR 2.095;95%CI 1.394-3.147;p<0.001)。
- 多因素分析中,N2或N3分期与较短无进展生存期显著相关(HR 2.145;95%CI 1.280-3.594;p=0.004)。
- 多因素分析中,年龄较大与较短总生存期相关(HR 1.040;95%CI 1.014-1.067;p=0.002)。
- 多因素分析中,N2或N3分期与较短总生存期相关(HR 2.427;95%CI 1.068-5.518;p=0.034)。
- 多因素分析中,胸腔积液与较短总生存期相关(HR 1.903;95%CI 1.105-3.276;p=0.020);远处转移与较短总生存期相关(HR 2.795;95%CI 1.356-5.765;p=0.005)。
临床应用与阅片要点
- 原文结论认为治疗前CT示胸腔积液和高N分期肿瘤与较短无进展生存期和总生存期相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to investigate adverse prognostic CT findings in patients with advanced-stage lung adenocarcinoma who are receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy as first-line therapy.
MATERIALS AND METHODS: We included 199 patients (71 men and 128 women; mean ± SD age, 64.3 ± 11.2 years) with stage IIIB or IV lung adenocarcinoma who received first-line EGFR-TKI therapy between January 2009 and December 2015. Clinical findings and imaging parameters on CT images obtained before TKI therapy were analyzed, including tumor size, TNM category according to the seventh edition of the American Joint Committee on Cancer lung cancer TNM staging system, tumor type, the presence of cavity or necrosis, pleural effusion, and metastasis to pleura, lung, and distant organs. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumor version 1.1 guidelines. Correlation of clinical and radiologic findings with durations of progression-free survival (PFS) and overall survival (OS) was evaluated using a Cox proportional hazard model.
RESULTS: Pleural effusion (hazard ratio [HR], 2.095; 95% CI, 1.394-3.147; p < 0.001) and an N2 or N3 tumor category (HR, 2.145; 95% CI, 1.280-3.594; p = 0.004) were significantly associated with a short PFS duration in multivariate analysis. Older age (HR, 1.040; 95% CI, 1.014-1.067; p = 0.002), an N2 or N3 tumor category (HR, 2.427; 95% CI, 1.068-5.518; p = 0.034), pleural effusion (HR, 1.903; 95% CI, 1.105-3.276; p = 0.020), and distant metastasis (HR, 2.795; 95% CI, 1.356-5.765; p = 0.005) were associated with a short OS duration in multivariate analysis.
CONCLUSION: Pre-TKI therapy CT findings of pleural effusion and high N-category tumors are associated with short durations of PFS and OS in patients with lung adenocarcinoma who are receiving EGFR-TKI therapy.
引用
- Chang S, Hur J, Hong YJ, et al. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. AJR Am J Roentgenol. 2017. PMID: 29091002. doi:10.2214/AJR.17.18167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。